- Home
- AEMD vs ADXN Comparison
AEMD vs ADXN Comparison
Compare AEMD & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEMD
- ADXN
- Stock Information
- Founded
- AEMD 1984
- ADXN 2002
- Country
- AEMD United States
- ADXN Switzerland
- Employees
- AEMD N/A
- ADXN N/A
- Industry
- AEMD Medical/Dental Instruments
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- AEMD Health Care
- ADXN Health Care
- Exchange
- AEMD Nasdaq
- ADXN Nasdaq
- Market Cap
- AEMD 8.2M
- ADXN 8.2M
- IPO Year
- AEMD N/A
- ADXN N/A
- Fundamental
- Price
- AEMD $0.42
- ADXN $7.10
- Analyst Decision
- AEMD Strong Buy
- ADXN Strong Buy
- Analyst Count
- AEMD 1
- ADXN 1
- Target Price
- AEMD $7.00
- ADXN $30.00
- AVG Volume (30 Days)
- AEMD 260.5K
- ADXN 8.5K
- Earning Date
- AEMD 02-12-2025
- ADXN 03-24-2025
- Dividend Yield
- AEMD N/A
- ADXN N/A
- EPS Growth
- AEMD N/A
- ADXN N/A
- EPS
- AEMD N/A
- ADXN 0.06
- Revenue
- AEMD N/A
- ADXN $701,260.00
- Revenue This Year
- AEMD N/A
- ADXN N/A
- Revenue Next Year
- AEMD N/A
- ADXN N/A
- P/E Ratio
- AEMD N/A
- ADXN $0.96
- Revenue Growth
- AEMD N/A
- ADXN N/A
- 52 Week Low
- AEMD $0.24
- ADXN $6.67
- 52 Week High
- AEMD $1.85
- ADXN $27.90
- Technical
- Relative Strength Index (RSI)
- AEMD 34.08
- ADXN 44.29
- Support Level
- AEMD $0.40
- ADXN $6.77
- Resistance Level
- AEMD $0.60
- ADXN $8.00
- Average True Range (ATR)
- AEMD 0.05
- ADXN 0.83
- MACD
- AEMD -0.01
- ADXN -0.10
- Stochastic Oscillator
- AEMD 13.41
- ADXN 10.75
About AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.